Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Precision Medicine Plan 'Golden Opportunity' For Device, Diagnostic Firms

This article was originally published in The Gray Sheet

Executive Summary

A new proposed framework to realize President Obama's Precision Medicine Initiative has significant potential for device and diagnostic companies, according to NIH Director Francis Collins. He says it will give them a "competitive opportunity" to develop cheaper whole genome sequencing tests and open the door to other exciting technologies.


Related Content

21st Century Cures: Device Provisions
21st Century Cures: Device Provisions
House Set To Vote On Cures Nov. 30; Latest Version Includes 510(k)s In Breakthrough Pathway
Workshop To Address NGS Draft Guidances
FDA Maps Out Novel Path For NGS Market Access
President Urges Breaking Down Drug, Device Distinctions, Regulatory Barriers
President Urges Breaking Down Of Drug, Device Distinctions, Regulatory Barriers
Expect Hybrid Design Concept/Performance Standards For NGS Regulatory Framework
FDA Nominee Califf Seeks Clinical Trial, Combo Product Reforms





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst